Skip to main
IMCR
IMCR logo

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings PLC has established a strong foundation for its growth potential through the successful commercialization of its primary product, KIMMTRAK, which has consistently surpassed sales expectations in 12 out of 14 quarters since its FDA and EMA approval in early 2022 for the treatment of unresectable or metastatic uveal melanoma. The company is strategically positioning itself for further expansion by leveraging the ImmTAX platform to develop a diverse pipeline of drug candidates across multiple treatment areas, including oncology, infectious diseases, and autoimmune conditions. Additionally, there is optimism regarding the potential for increased market penetration in the U.S. and further growth opportunities internationally, which could enhance the company's overall revenue trajectory.

Bears say

Immunocore Holdings's stock faces a negative outlook due to disappointing data disclosures from clinical trials, particularly in cutaneous melanoma and ovarian cancer, where the objective response rates (ORR) were significantly below market expectations, with only 11% and 6% respectively. Furthermore, the emergence of competitive products, particularly IDYA's darovasertib and its combination with crizotinib, threatens to diminish the market potential for KIMMTRAK, especially in the HLA-A2+ metastatic uveal melanoma segment. Additionally, risks associated with research and development setbacks, regulatory challenges, and the potential for dilutive financing compound the uncertainties affecting the company's financial stability and stock performance.

Immunocore Holdings (IMCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 7 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.